Evoworks Bio today announced its platform technology has been selected for BioTools Innovator VANGUARD Funding, powered by BioTools Innovator (BTI) in partnership with the Biomedical Advanced Research and Development Authority (BARDA).* Evoworks is one of five awardees to receive non-dilutive funding to advance promising technologies for health security. The program will fund the production of key biologics in the EvoNode platform, the world’s first elastically scalable vessel for cell culture and protein expression.
“Evoworks is excited to work with best-in-class protein developers Kemp Proteins and Rockland Immunochemical to demonstrate rapid production of critical biologics for national readiness,” said Ross Beighley, CEO and Founder of Evoworks Bio.
“There is a fundamental gap between the lab and the manufacturing floor. This funding lets us close that gap with the EvoNode platform, allowing teams to move from flasks to high-volume, quality production in their own labs. We’re aiming to cut overall costs for quality scale-up by 75% in addition to timeline and risk reduction.”
Chosen from more than 170 applicants, the VANGUARD awardees represent the most promising innovations in life science tools for bioanalysis, diagnostics, drug discovery, and biomanufacturing that can play a critical role in U.S. health security. Over the 6-month program, participants will work closely with BARDA experts, receive targeted mentorship, and engage with the BioTools Innovator network.
On this project, Evoworks Bio will produce and validate a panel of critical antibodies on the EvoNode platform, with Rockland Immunochemicals providing representative monoclonal antibody (mAb)-producing cell lines to support the evaluation of scale-up performance, process transferability, and production outcomes, and Kemp Proteins applying their experience working with stable cell lines, the Ambr® system, and STTR workflows.
Read Also: DEMETRA ANNOUNCES A STRATEGIC COLLABORATION WITH MASMEC BIOMED
